Acute Coronary Syndrome Clinical Trial
— CathEFOfficial title:
Prospective Validation of a Deep Learning Algorithm for Prediction of the Left Ventricular Ejection Fraction From Coronary Angiogram Videos in Patients With Acute Coronary Syndrome
NCT number | NCT05317286 |
Other study ID # | CathEF |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 1, 2022 |
Est. completion date | February 29, 2024 |
Verified date | March 2024 |
Source | Montreal Heart Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Left ventricular ejection fraction (LVEF) is one of the strongest predictors of mortality and morbidity in patients with acute coronary syndrome (ACS). Transthoracic echocardiography (TTE) remains the gold standard for LVEF measurement. Currently, LVEF can be estimated at the time of the coronary angiogram but requires a ventriculography. This latter is performed at the price of an increased amount of contrast media injected and puts the patients at risk for mechanical complications, ventricular arrhythmia or atrio-ventricular blocks. Artificial intelligence (AI) has previously been shown to be an accurate method for determining LVEF using different data sources. Fur the purpose of this study, we aim at validating prospectively an AI algorithm, called CathEF, for the prediction of real-time LVEF (AI-LVEF) compared to TTE-LVEF and ventriculography in patients undergoing coronary angiogram for ACS.
Status | Completed |
Enrollment | 240 |
Est. completion date | February 29, 2024 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Informed consent signed by the participant - Acute coronary syndrome - Creatinine clearance =30 ml/min/m2 according to MDRD Exclusion Criteria: - Creatinine clearance <30 ml/min/m2 according to MDRD - No indication to perform TTE in the 7 days following coronary angiogram - Right bundle branch block - Suspected or confirmed left ventricular thrombus - Suspected or confirmed aortic dissection - Ventriculography not feasible - No left coronary system angiogram |
Country | Name | City | State |
---|---|---|---|
Canada | Robert Avram | Montreal | Quebec |
Lead Sponsor | Collaborator |
---|---|
Montreal Heart Institute | Ottawa Heart Institute Research Corporation |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Area under the curve-Receiver Operating Characteristics (AUC-ROC) of the CathEF algorithm for differentiating a LVEF = or >50%, compared to TTE-LVEF | Either 7 days before or up to 7 days after the coronary angiogram | ||
Secondary | Comparing AUC-ROC of CathEF and ventriculography for differentiating a LVEF = or >50% | Either 7 days before or up to 7 days after the coronary angiogram | ||
Secondary | Sensitivity of CathEF and ventriculography for differentiating a LVEF = or >50% in comparison to TTE-LVEF. | Either 7 days before or up to 7 days after the coronary angiogram | ||
Secondary | Specificity of CathEF and ventriculography for differentiating a LVEF = or >50% in comparison to TTE-LVEF. | Either 7 days before or up to 7 days after the coronary angiogram | ||
Secondary | Number of participants with major adverse cardiovascular events (Combined outcome of combined outcomeof mortality, ventricular arrhythmia requiring an intervention, heart failure, need for inotropic support, renal failure KDIGO=2 and stroke) | At 7 days or before discharge, if earlier. | ||
Secondary | AUC-ROC of the re-trained CathEF algorthim for differentiating a LEVF = or >50% | Either 7 days before or up to 7 days after the coronary angiogram | ||
Secondary | Sensitivity of the re-trained CathEF algorthim for differentiating a LEVF = or >50% | Either 7 days before or up to 7 days after the coronary angiogram | ||
Secondary | Specificity of the re-trained CathEF algorthim for differentiating a LEVF = or >50% | Either 7 days before or up to 7 days after the coronary angiogram | ||
Secondary | Likert scale on the impact on the procedure, ease of use and utility of the CathEF algorithm in the clinical practice, as assessed by interventional cardiologists | Through study completion, an average of 1 year. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06013813 -
Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT05412927 -
AngelMed Guardian® System PMA Post Approval Study
|
||
Completed |
NCT02750579 -
Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes?
|
N/A | |
Completed |
NCT04102410 -
Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients
|
N/A | |
Enrolling by invitation |
NCT03342131 -
Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome
|
N/A | |
Recruiting |
NCT01218776 -
International Survey of Acute Coronary Syndromes in Transitional Countries
|
||
Enrolling by invitation |
NCT04676100 -
International CR Registry
|
||
Completed |
NCT03590535 -
5th Generation cTnT in ED ACS
|
||
Recruiting |
NCT05437900 -
INSIGHTFUL-FFR Clinical Trial
|
Phase 4 | |
Completed |
NCT05551429 -
Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
|
||
Terminated |
NCT04316481 -
IDE-ALERTS Continued Access Study
|
N/A | |
Active, not recruiting |
NCT04475380 -
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
|
||
Not yet recruiting |
NCT04852146 -
Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
|
||
Active, not recruiting |
NCT02892903 -
In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?
|
N/A | |
Completed |
NCT02944123 -
Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)
|
Phase 3 | |
Completed |
NCT04077229 -
Piloting Text Messages to Promote Positive Affect and Physical Activity
|
N/A | |
Not yet recruiting |
NCT02871622 -
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
|
N/A | |
Active, not recruiting |
NCT02922140 -
The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit
|
N/A | |
Completed |
NCT02673437 -
Rivaroxaban ACS Specialist Cohort Event Monitoring Study
|